Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Cash from Financing Activities (2020 - 2025)

GeneDx Holdings has reported Cash from Financing Activities over the past 6 years, most recently at $23.2 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $23.2 million for Q4 2025, down 25.24% from a year ago — trailing twelve months through Dec 2025 was $48.0 million (up 8.75% YoY), and the annual figure for FY2025 was $48.0 million, up 8.75%.
  • Cash from Financing Activities for Q4 2025 was $23.2 million at GeneDx Holdings, up from $10.8 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for WGSWW hit a ceiling of $499.4 million in Q3 2021 and a floor of -$2.4 million in Q2 2021.
  • Median Cash from Financing Activities over the past 5 years was $3.9 million (2023), compared with a mean of $48.5 million.
  • Biggest five-year swings in Cash from Financing Activities: surged 83011.25% in 2023 and later tumbled 105.29% in 2024.
  • GeneDx Holdings' Cash from Financing Activities stood at -$1.0 million in 2021, then soared by 106.32% to $65000.0 in 2022, then surged by 72366.15% to $47.1 million in 2023, then plummeted by 34.14% to $31.0 million in 2024, then decreased by 25.24% to $23.2 million in 2025.
  • The last three reported values for Cash from Financing Activities were $23.2 million (Q4 2025), $10.8 million (Q3 2025), and $346000.0 (Q2 2025) per Business Quant data.